Fig. 2.

PASI75, PASI90, and PASI100 response rates at week 16 overall and by type of prior failed systemic therapy. Patients from Study M02-528 were excluded because it was a 12-week study. ADA adalimumab, PASI75, PASI90, and PASI100 improvement of ≥75, ≥90, and 100 % from baseline, respectively, in the Psoriasis Area and Severity Index score, PBO placebo, PUVA psoralen plus ultraviolet A. *p ≤ 0.001 compared with placebo